LEXICON PHARMACEUTICALS, INC. Restructuring and Related Cost, Cost Incurred to Date
LEXICON PHARMACEUTICALS, INC. (LXRX) had Restructuring and Related Cost, Cost Incurred to Date of $5.60 million as of 2014-12-31, per its 10-K filed 2015-03-12.
Discontinued › Notes
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2015-03-12
- 2014-12-31: Restructuring and Related Cost, Cost Incurred to Date $5.60M.
- 2014-09-30: Restructuring and Related Cost, Cost Incurred to Date $5.60M.
- 2014-06-30: Restructuring and Related Cost, Cost Incurred to Date $5.40M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2014-12-31 | $5.60M 10-K · filed 2015-03-12 |
| 2014-09-30 | $5.60M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $5.40M 10-Q · filed 2014-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |